Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0
Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition

Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition
Item 2.02

​

On July 23, 2020, HarborOne Bancorp, Inc. (the “Company”), the holding company for HarborOne Bank, issued a press release announcing its financial results for the quarter ended June 30, 2020. The Company’s press release is included as Exhibit 99.1 to this report.

​

The information set forth in this Item 2.02 and in the attached Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section.

​

​

Item 9.01Financial Statements and Exhibits

​

(d)Exhibits

​

​

​

EXHIBIT INDEX

​

​

​

​

​

​

​

​

​

HarborOne Bancorp, Inc. Exhibit
EX-99.1 2 hone-20200723xex99d1.htm EX-99.1 Exhibit 99.1​HarborOne Bancorp,…
To view the full exhibit click here

About Inc. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.